U.S. markets open in 5 hours

RedHill Biopharma Ltd. (REDIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.67000.0000 (0.00%)
At close: 2:13PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6700 - 0.6700
52 Week Range0.6700 - 0.6700
Avg. Volume0
Market Cap164.631M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.3110
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for REDIF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      RedHill Biopharma to Present at the BIO-Europe 2021 Conference

      RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present a corporate overview at the BIO-Europe Digital Conference, taking place October 25-28, 2021.

    • Benzinga

      David v Goliath in The Race to Develop an Oral Therapy for COVID-19

      Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19 can agree on, is the urgent need for oral, pill-based treatments that are effective at halting disease progression, can get — and keep — people out of the hospital and can reduce mortality. One key group of COVID-19 patients who are in desperate need of treatment options are those moderately severe patients in hospital


      RedHill Biopharma Announces Insider Buying

      TEL-AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / October 18, 2021 / RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, CFO, Chief Commercial Officer, Chief Business Officer and Chief Corporate & Business Development Officer, collectively purchased approximately 180,000 American Depositary Shares (ADSs) of RedHill between mid-